Lilia Flores, OD
Optometrist · Dallas, TXNPI 1265911317
Payments from drug & device makers
Across 150 payments — averaging $149.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Rxsight Inc$18K
- Biotissue Holdings Inc.$1K
- Alcon$801
- AbbVie$745
- Johnson & Johnson Surgical Vision, Inc.$263
- Shire North American Group Inc$251
- plus $1K from 17 others
What the payments were for
- Consulting fees$16,73774%
- Speaking & faculty fees$260%
- Food & beverage$5,58525%
- Gifts$190%
- Entertainment$1060%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Rxsight Inc | 29 | $17,735 |
| Biotissue Holdings Inc. | 44 | $1,466 |
| Alcon | 7 | $801 |
| AbbVie | 20 | $745 |
| Johnson & Johnson Surgical Vision, Inc. | 6 | $263 |
| Shire North American Group Inc | 10 | $251 |
| Novartis | 4 | $155 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 4 | $139 |
| Amgen(2 entities) | 4 | $135 |
| Tarsus Pharmaceuticals, Inc. | 5 | $132 |
| Aerie Pharmaceuticals, Inc. | 1 | $122 |
| Optos, Inc. | 1 | $106 |
| Astellas Pharma US Inc | 1 | $103 |
| Bausch & Lomb Americas Inc. | 2 | $96 |
| Kala Pharmaceuticals, Inc. | 3 | $51 |
| Oyster Point Pharma, Inc. | 2 | $35 |
| Sun Pharmaceutical Industries Inc. | 1 | $23 |
| Dompe US, Inc. | 1 | $22 |
| Mallinckrodt Enterprises LLC | 1 | $21 |
| Thea Pharma Inc. | 1 | $21 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Eyevance Pharmaceuticals LLC | 1 | $15 |
| Lensar, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RXSIGHT CONTACT LENS$17,379
- RXSIGHT INJECTOR CARTRIDGE$17,379
- RXSIGHT INJECTOR HANDPIECE$17,379
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$17,379
- LIGHT ADJUSTABLE LENS (LAL)$14,278
- RXSIGHT LIGHT ADJUSTABLE LENS (RXLAL)$3,101
- Clareon$255
- DURYSTA$245
- AcrySof IQ PanOptix UV IOL$238
- PANORAMIC OPHTHALMOSCOPE$213
- OCT OPHTHALMOSCOPE$213
- Prokera$195
- AmnioGraft$195
- ARGOS$144
- Tecnis Simplicity$137
- AcrySof IQ VIVITY$136
- TOTAL30$125
- TRAVATAN Z$124
- XIIDRA$122
- Rhopressa$122
How this compares
$22,473 in reported general payments places this provider in the 95th percentile of 4,315 optometrist providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Restasis MultidoseCyclosporine | 31 | $19,556 |
| RestasisCyclosporine | 31 | $17,639 |
| XiidraLifitegrast | 18 | $17,552 |
| Lotemax SmLoteprednol Etabonate | 12 | $2,956 |
| Latanoprost | 185 | $1,996 |
| Timolol Maleate | 57 | $827 |
| Prednisolone Acetate | 26 | $716 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 42 | $499 |
| Dorzolamide Hcl | 21 | $464 |
| Brimonidine Tartrate | 42 | $335 |
| MoxifloxacinMoxifloxacin Hcl | 12 | $301 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 20 | $227 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis Multidose, Restasis | $745 | $37,19462 claims |
| Bausch & Lomb Americas Inc.Xiidra | $96 | $17,55218 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm | $139 | $2,95612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,315 optometrist providers in Texas.
Other optometrist in Dallas
- Laurence ThomasDallas$103K
- Kenneth UzickDallas$61K
- Paola DiazDallas$58K
- Amanda HoelscherDallas$44K
- Tiffany HuynhHouston$3.2M
- Bridgitte LeeHouston$3M
- Bryan FrazierTyler$1.4M
- Derek CunninghamAustin$940K
- Wendy ChungKaty$900K
- Phillip BrunsonHouston$766K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.